A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
Bausch Health Americas, Inc. · NCT07187297
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 30–60 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 164
- US sites recruiting
- 7
- Study start
- October 31, 2025
- Record last updated
- August 26, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
A prospective, 180-day, randomized, multicenter, independent blinded evaluators, controlled study of treatment with the Thermage FLX System
Being studied: Thermage FLX
Conditions: Wrinkle; Lax Skin; Lines Skin
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Be an adult female or male, ≥30 - ≤60 years of age.
Have mild-to-moderate skin laxity of the neck, abdomen, upper arms, and/or face, and/or mild-to-moderate lines and/or wrinkles of the neck and/or face assessed as follows:
Neck
Mild-to-moderate neck skin laxity as defined by a score of 1 to 6 on the 10-point Facial Laxity Rating Scale (scored 0-9)
Mild-to-moderate neck wrinkles as defined by a score of 1 to 6 on the 10-point Fitzpatrick Wrinkle Scale (scored 0-9)
Abdomen
Mild-to-moderate abdomen skin laxity as defined by a score of 1 or 2 on a 4-point Abdominal Laxity Scale (scored 0-3)
Upper arms
Mild to moderate upper arms skin laxity as defined by grade 2 or 3 on the 5-grade IBSA Inner Upper Arm Laxity Scale
Face
Mild-to-moderate facial skin laxity as defined by a score of 1 to 6 on the 10-point Facial Laxity Rating Scale (scored 0-9)
Mild-to-moderate facial wrinkles as defined by a score of 1 to 6 on the 10-point Fitzpatrick Wrinkle Scale (scored 0-9)
Females of childbearing potential must have a negative urine pregnancy test. Females who have experienced menarche and who are not postmenopausal (either confirmed via FSH testing or who have not menstruated for 2 years or more without an alternative medical cause) or surgically sterile will be considered of childbearing potential.
Females of childbearing potential must agree to use an acceptable method of birth control for the duration of the study. Acceptable methods of birth control are oral and other systemic contraceptives, condoms only, intrauterine device, double-barrier methods, bilateral tubal ligation, partner vasectomy, and abstinence.
Have no clinically abnormal findings based on the medical history as determined by the study investigator.
Be able to follow the study instructions, be available on the specific required study visit days, and be willing to complete all study visit procedures and assessments.
Understand the research nature of this study and sign an informed consent document prior to the performance of any study-specific procedure or assessment.
Agree to not undergo excluded procedures (i.e., energy-based device treatments, injectables, or plastic surgery) on the study treatment areas for the duration of study.
Participant has a body mass index (BMI) ≤30.
Exclusion Criteria
- Participant is pregnant or breast feeding or trying to become pregnant for 3 months prior to the screening visit or during the study.
Participant has given birth within 3 months prior to the screening visit.
Participant has an anticipated need for procedures, surgery, overnight hospitalization, or other events that would prevent the participant from making the required visits during the study.
Participant has a pacemaker, internal defibrillator, or other implanted electronic device.
Participant has an implant in the target treatment zone(s).
Participant has had radiation therapy in the target treatment zone(s).
Participant has had 1 or more prior cosmetic procedures in the target treatment zone(s) including:
Thermage or any energy-based device procedure, derm abrasion, or chemical peel on any treatment area within 6 months prior to the screening visit.
Short-acting neurotoxins within 6 months prior to the screening visit.
Long-acting neurotoxins within 9 months prior to the screening visit.
Hyaluronic acid filler ≤1 year prior to the screening visit.
Semi-permanent or permanent fillers at any time prior to the screening visit.
Plastic surgery within 1 year prior to the screening visit.
Recruiting US locations
Laser & Skin Surgery Center of Northern California
Sacramento, CA 95816
Site contact: Julie Caselli · 916-768-0400 · study@skinlasers.com
Cosmetic Laser Dermatology
San Diego, CA 92121
Site contact: Abigail Reyes · 858-657-1004 · Abigail.reyes@platinumderm.com
Cosmetic Laser Dermatology
San Diego, CA 92121
Site contact: Douglas Wu · 858-657-1002 · dwu@clderm.com
Chicago Cosmetic Surgery and Dermatology
Chicago, IL 60654
Site contact: Kevin Zaragoza · 312-245-9965 · kzaragoza@chicagodermatology.com
SkinCare Physicians
Chestnut Hill, MA 02467
Site contact: Joaninha Barbosa · 617-731-1600 · jdepina@skincarephysicians.net
Union Square Laser Dermatology
New York, NY 10003
Site contact: Kathyrn Salvador · 212-366-5400 · research@unionderm.com
Dermatology and Laser Surgery Center
Houston, TX 77004
Site contact: Annie Li · 713-900-3900 · research@dermlasersurgery.com
Study contacts (from the official record)
- Sandra Narain · 9082428287 · sandra.narain@bauschhealth.com
- Caitlin Little · caitlin.little@premier-research.com
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55